Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT07617376
Recruiting Phase 4

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

NCT07617376 · tracked via the Priya Life Science Poland tracker
Sponsor
Wroclaw Medical University
Phase
Phase 4
Started
2025-11-12
Last updated
2026-06-01

Condition(s) studied

Myocardial InfarctionDecompensated Chronic Heart FailureAcute Heart Failure (AHF)Pulmonary Embolism AcuteHypertension EmergencyArrhythmias

Investigational drug(s) / intervention(s)

Influenza vaccination →

Influenza vaccination: Influenza vaccination pre-discharge in patients hospitalized for acute cardiac conditions

Study summary

Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.

In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Acute cardiac hospitalization, * Planned discharge home within the next 48 hours following completion of in-hospital treatment, * No prior influenza vaccination for the current influenza season. Exclusion Criteria: * History of a severe adverse reaction to influenza vaccination, * Allergy to any component of the vaccine to be administered, * Discharge to another hospital for continuation of treatment or discharge to a long-term care facility, * Antibiotic therapy to be continued after discharge.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Jan Mikulicz Radecki University Hospital in Wroclaw Wroclaw Poland Recruiting

More Wroclaw Medical University trials in Poland

The Impact of Expandable Cryoballoon on Autonomic Control of the Heart Active, not recruiting
Effectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management Enrolling by invitation
Selected Disorders and Sleep Bruxism Enrolling by invitation
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin Enrolling by invitation
Evaluation of the Factors Associated With BRADYcardia Following Pulmonary Vein Isolation Using Pulsed Field Ablation Recruiting

Other trials for the same condition

Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation Recruiting
Simultaneous Cardiac Surgery and Micronet-covered Stent Carotid Revascularization in High Perioperative Stroke Risk Patients Recruiting
Investigation to Assess the Effects of Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes Starting soon
Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study Recruiting
Functional Assessment in Elderly MI Patients With Multivessel Disease Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07617376 on ClinicalTrials.gov ↗ ← All trials in Poland